Development of Biodegradable and Injectable Latices for Controlled Release of Potent Drugs

Gurny, Robert; Peppas, Nicholas A.; Harrington, Daniel D.; Banker, Gilbert S.

doi:10.3109/03639048109055684

Cited by 170 publications

(57 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LTZ-PLGA-NPs were prepared by emulsion-solvent evaporation method (single emulsion technique) proposed first by Gurny et al (1981) and based on the classical procedure patented by Vanderhoff et al (1979). Briefly, LTZ (10-40% w/w) was dissolved in 2 mL of the Dichloromethane, containing 25 mg of PLGA.…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy

Dey¹,

Mandal²,

Bhowmik³

et al. 2009

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The objectives of our study were to prepare and evaluate a biodegradable nanoparticulate system of Letrozole (LTZ) intended for breast cancer therapy. LTZ loaded poly(lactide-co-glycolide) nanoparticles (LTZ-PLGA-NPs) were prepared by emulsion-solvent evaporation method using methylene chloride and polyvinyl alcohol. Percentage of drug (with respect to polymer) was selected as formulation variable. LTZ-PLGA-NPs were characterized by particle size, zeta potential, infrared spectra, drug entrapment efficiency and in vitro release. Sonication was done with an ultrasound pulse sonicator at 70 W, 30 kHz for 90 sec to produce stable NPs of mean size range from 64 nm to 255 nm with high entrapment efficiency (68% to 82%). Percentage of drug significantly influenced particle size, entrapment efficiency and release (p <0.05). The system sustained release of LTZ significantly and further investigation could exhibit its potential usefulness in breast cancer therapy.Uniterms: Breast cancer/therapy. Letrozole. Biodegradable nanoparticles.Os objetivos de nosso estudo foram preparar e avaliar o sistema de nanopartícula biodegradável de letrozol na terapia de câncer mamário. Nanopartículas de poli(lactídeo-co-glicolídeo) carregadas com LTZ (LTZ-PLGA-NPs) foram preparadas pelo método de emulsão-evaporação de solvente, utilizando dicloro metano e álcool polivinílico. A porcentagem do fármaco (com relação ao polímero) foi selecionada como variável da formulação. LTZ-PLGA-NPs foram caracterizadas pelo tamanho da partícula, potencial zeta, espectros no infravermelho, eficiência de inclusão e liberação in vitro. A sonicação foi realizada com sonicador de ultrassom, de pulso a 70W e 30 kHz por 90 segundos para produzir NPs estáveis, de faixa de tamanho médio de 64 nm a 266 nm, com alta eficiência de inclusão (68% a 82%). A porcentagem do fármaco foi significativamente influenciada pelo tamanho da partícula, eficiência de inclusão e liberação (p<0,05). O sistema controlou significativamente a liberação de LTZ e estudos posteriores poderiam mostrar sua utilidade potencial na terapia de câncer de mama. Unitermos: Câncer de mama/terapia. Letrozol. Nanopartícula biodegradável.

show abstract

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy

Dey¹,

Mandal²,

Bhowmik³

et al. 2009

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…PlGA nanocarriers have previously been investigated for application in IBD as delivery systems for 5-aminosalicylic acid and tacrolimus and after chitosan surface modification for localized delivery of nuclear factor kappa decoy oligonucleotide (tahara et al, 2011). to increase their stability in low pH and target the drug release to the distal ileum and colon, PlGA can also be blended with eudragit S100 (Gurny et al, 1981;Makhlof et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…From this modified polymer budesonide loaded FA-PlGA nanoparticles were prepared using the emulsion solvent evaporation method (Gurny et al, 1981;Metselaar and Storm, 2005). Briefly, 45 mg of budesonide base was dissolved at room temperature in 15 ml of ethylacetate containing 300 mg of FA-PlGA.…”

Section: Fabrication and Characterization Of Budesonide Loaded Plga Nmentioning

confidence: 99%

Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model

Leonard

Ali²,

Collnot

et al. 2012

ALTEX

View full text Add to dashboard Cite

Summary Drug formulation screenings for treatment of inflammatory bowel disease (IBD) are mostly conducted in chemically induced rodent models that represent acute injury-caused inflammation instead of a chronic condition. To accurately screen drug formulations for chronic IBD, a relevant model that mimics the chronic condition in vitro is urgently needed. In an effort to reduce and potentially replace this scientifically and ethically questionable animal testing for IBD drugs, our laboratory has developed an in vitro model for the inflamed intestinal mucosa observed in chronic IBD, which allows high-throughput screening of anti-inflammatory drugs and their formulations. The in vitro model consists of intestinal epithelial cells, human blood-derived macrophages, and dendritic cells that are stimulated by the inflammatory cytokine interleukin-1β. In this study, the model was utilized for evaluation of the efficacy and deposition of budesonide, an anti-inflammatory drug, in three different pharmaceutical formulations: (1) a free drug solution, (2) encapsulated into PLGA nanoparticles, and (3) encapsulated into liposomes. The in vitro model of the inflamed intestinal mucosa demonstrated its ability to differentiate therapeutic efficacy among the formulations while maintaining the convenience of conventional in vitro studies and adequately representing the complex pathophysiological changes observed in vivo.

show abstract

“…It was not until 1981 that the first nanoparticles of poly (lactic-co-glycolic) acid were described by Gurny [75]. These nanoparticles were especially challenging to prepare due to their poor solubility in organic solvents, and the fact that they cannot be directly polymerised.…”

Section: Peptidic Nanoparticlesmentioning

confidence: 99%

The role of peptides in blood‐brain barrier nanotechnology

Teixidó

Giralt

2007

Journal of Peptide Science

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB) regulates the passage of molecules between the bloodstream and the brain. Overcoming the difficulty of delivery drugs to specific areas of the brain is a major challenge. The BBB exerts a neuroprotective function as it hinders the delivery of diagnostic and therapeutic agents to the brain. Here, we provide an overview of the way in which peptides and nanotechnology are being exploited in tandem to address this problem. Peptides can be used as specialised coatings able to transport nanoparticles with specific properties, such as targeting. The nanoparticle can also carry a peptide drug. Furthermore, peptides can be used in less conventional approaches such as all-peptide nanoparticles. In summary, the combined use of peptides and nanotechnology offers tremendous hope in the treatment of brain disorders.

show abstract

Development of Biodegradable and Injectable Latices for Controlled Release of Potent Drugs

Cited by 170 publications

References 23 publications

Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy

Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy

Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model

The role of peptides in blood‐brain barrier nanotechnology

Contact Info

Product

Resources

About